Teva Pharmaceutical Industries Limited announces successful pricing of Regulation S offerings of senior notes.
On April 2, Willkie client Teva Pharmaceutical Industries Limited announced that it successfully priced its debut EUR and CHF-denominated debt offerings. The offerings comprise an aggregate of EUR 1 billion of 2.875% senior notes due 2019 and CHF 450 million of 1.500% senior notes due 2018 issued by finance subsidiaries, Teva Pharmaceutical Finance IV B.V. and Teva Pharmaceutical Finance V B.V., each guaranteed by Teva. The offerings are being made outside the United States to non-U.S. persons in reliance on Regulation S under the U.S. Securities Act. Headquartered in Israel with approximately 46,000 employees around the world and $18.3 billion in net revenues in 2011, Teva is among the top pharmaceutical companies in the world and is the leading generic pharmaceutical company.
Willkie recently advised Teva on its $5 billion offering of senior notes in the largest securities offering by an Israeli company and on its consumer health care joint venture with The Procter & Gamble Company.
The Regulation S offerings were handled by partner Jeffrey Hochman and associates Leah Fix and Rebecca Villarreal in New York, with the assistance of partner Jon Lyman and associate Ann Harrington in London and national partner Julien Mougel in Paris.